Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic nodal or visceral metastasis who were treated with the combination therapy of cabozantinib plus atezolizumab had significantly improved time to disease progression compared to those who were treated with hormonal therapy. This research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27 in San Francisco, California.
January 22, 2024
January 20, 2024
The dual immunotherapy combination of nivolumab and ipilimumab reduced the risk of disease progression or death by 79% compared to chemotherapy with or without targeted therapies as first-line treatment in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.
January 20, 2024
Ten studies exploring new approaches for the treatment of gastrointestinal cancers will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place in San Francisco, CA, and online, January 18-20.
January 19, 2024
The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (uHCC) that were eligible for embolization. According to the authors, this is the first trial to demonstrate improved clinical outcomes for immunotherapy-based combinations with TACE in these patients. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online.
January 19, 2024
Results from the first phase 3 clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with [177Lu]Lu-DOTA-TATE significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic neuroendocrine tumors, potentially establishing a new standard of care. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.
January 17, 2024
The Centers for Medicare & Medicaid Services (CMS) issued its rule requiring federal health plans—including Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs)— to establish an electronic prior authorization process that will be integrated into providers’ workflows.
January 16, 2024
Results from a new phase III study found that combining PD-L1and TIGIT inhibitors plus chemotherapy in the first-line setting prolongs survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell carcinoma. This treatment combination has the potential to boost the body's ability to fight cancer and may ultimately lead to better outcomes for these patients with esophageal squamous cell carcinoma that cannot be surgically removed or has spread to other parts of the body. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.
January 16, 2024
The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor cancer treatment, remains unclear after the first prospective randomized phase II trial evaluating clearance of ctDNA as a primary endpoint using adjuvant chemotherapy in patients with stage II colon cancer did not meet its endpoint. The NRG-GI005 (COBRA) phase II/III study was halted after the results of the pre-planned phase II analysis found that the use of chemotherapy did not increase the rate of ctDNA clearance among patients who had detectable ctDNA after surgery when compared to patients who did not receive chemotherapy. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online.
January 16, 2024
Following surgery to remove a tumor, patients may have molecular residual disease (MRD), or a small amount of cancer cells that remain in the body but are too small to be detected with imaging. ctDNA, or liquid biopsy, may be used to detect MRD in patients who underwent surgery for colorectal cancer and determine if they will benefit from receiving adjuvant chemotherapy. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.
January 10, 2024
The latest research exploring innovative approaches for the detection and treatment of prostate, bladder, and kidney cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 700 abstracts that will be presented at the meeting.
January 9, 2024
A new call-to-action published today, January 9, in the journal Cancer details practical steps for the oncology research and clinical care communities to expand access to clinical trials and enable patients to participate closer to their homes.
December 19, 2023
Six studies exploring new approaches for the treatment of gastrointestinal cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. The research includes circulating tumor DNA (ctDNA) in colorectal cancer and new treatment options for pancreatic, liver, and esophageal cancers. Studies featured in the Press Program are among the more than 750 abstracts that will be presented at the Symposium.
December 15, 2023
ASCO has elected Eric J. Small, MD, FASCO, to lead as its President beginning in June 2025.
December 11, 2023
ConcertAI today announced the acquisition of CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO). In conjunction with the acquisition, ASCO will maintain a multi-year cooperation agreement with CancerLinQ. Building on CancerLinQ’s mission when launched by ASCO in 2013, this new venture will enhance and expand CancerLinQ’s use of real-world data, analytics, next-generation AI, and other technologies to improve cancer care and speed clinical research.
November 17, 2023
President Biden announced on Nov. 17, 2023, the appointment of W. Kimryn Rathmell, MD, PhD, Chair of Medicine at Vanderbilt University Medical Center, and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics, as his choice for director of the National Cancer Institute (NCI).
Pages |